Top 10 Companies in the (R)-2‑Hydroxybutyrolactone (CAS 56881‑90‑4) Market (2026): Market Leaders Powering Global Chemistry

MARKET INSIGHTS

Global (R)-2‑Hydroxybutyrolactone (CAS 56881‑90‑4) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 7.3% during the forecast period.

(R)-2‑Hydroxybutyrolactone (CAS 56881‑90‑4) is a chiral lactone belonging to the gamma‑butyrolactone family. It is a colorless to pale yellow liquid that delivers high optical purity and serves as a versatile chiral building block in asymmetric synthesis. The compound is widely employed in pharmaceutical intermediates, agrochemical synthesis, and fine chemical manufacturing.

The market is witnessing steady growth, primarily driven by the expanding demand for chiral intermediates in pharmaceutical synthesis and the broader shift toward enantioselective drug development. Rising adoption of green chemistry principles and a focus on stereospecific synthesis reinforce the compound’s relevance across research and industrial applications. Key suppliers include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar, among other specialty chemical manufacturers with established chiral chemistry portfolios.

(R)-2‑Hydroxybutyrolactone (CAS 56881‑90‑4) Market – View in Detailed Research Report

Top 10 Companies in the (R)-2‑Hydroxybutyrolactone Market

1. Tokyo Chemical Industry Co., Ltd. (Japan)

   Headquarters: Tokyo, Japan
   Key Offering: High‑purity (R)-2‑Hydroxybutyrolactone for API synthesis

   TCI’s proprietary asymmetric synthesis platform delivers enantiomeric excess above 99.9% with minimal impurities. The company’s integrated supply chain supports large‑scale production for pharmaceutical manufacturers, ensuring consistent delivery to global clients.

   Sustainability & Growth Initiatives:

   • Investment in continuous flow reactors to reduce solvent use by 30%
   • Partnerships with academic institutions to develop greener biocatalytic routes
   • Commitment to ISO 14001 environmental management across all production sites

2. Merck KGaA (via Sigma‑Aldrich) (Germany)

   Headquarters: Darmstadt, Germany
   Key Offering: GMP‑grade (R)-2‑Hydroxybutyrolactone for drug intermediates

   Merck’s global distribution network and GMP certification make it a trusted partner for pharma companies seeking reliable chiral intermediates. Its advanced chromatographic separation processes maintain purity levels above 99.8% while meeting stringent regulatory requirements.

   Sustainability & Growth Initiatives:

   • Adoption of renewable feedstocks for gamma‑butyrolactone precursors
   • Implementation of closed‑loop water recycling in synthesis units
   • Active participation in the European REACH compliance program

3. Thermo Fisher Scientific Inc. (USA)

   Headquarters: Waltham, Massachusetts, USA
   Key Offering: Custom synthesis of (R)-2‑Hydroxybutyrolactone for specialty applications

   Thermo Fisher’s contract‑manufacturing arm provides tailored solutions for biotech and fine‑chemical developers, leveraging its state‑of‑the‑art chiral resolution facilities to deliver high‑purity intermediates on demand.

   Sustainability & Growth Initiatives:

   • Integration of bio‑catalytic processes to cut energy consumption by 15%
   • Development of modular flow‑chemistry platforms for rapid scale‑up
   • Transparent reporting of carbon footprint for each batch

4. PharmaBlock (Nanjing) Co., Ltd. (China)

   Headquarters: Nanjing, China
   Key Offering: Large‑scale production of (R)-2‑Hydroxybutyrolactone for API manufacturers

   PharmaBlock’s GMP‑certified facilities and proximity to raw‑material sources enable cost‑competitive supply of chiral intermediates, supporting the rapid expansion of China’s generic drug sector.

   Sustainability & Growth Initiatives:

   • Implementation of energy‑efficient distillation towers
   • Use of locally sourced, low‑toxicity reagents to minimize environmental impact
   • Collaboration with local universities to train the next generation of chiral chemists

5. Changzhou Comwin Fine Chemicals Co., Ltd. (China)

   Headquarters: Changzhou, China
   Key Offering: GMP‑grade (R)-2‑Hydroxybutyrolactone for pharma and agrochemical applications

   Comwin’s focus on process optimization and scale‑up has positioned it as a preferred supplier for both domestic and international customers seeking reliable chiral intermediates.

   Sustainability & Growth Initiatives:

   • Adoption of enzymatic resolution techniques to reduce solvent usage
   • Investment in waste‑to‑energy conversion for process by‑products
   • Participation in China’s “Green Chemistry” certification program

6. Biosynth Carbosynth (Switzerland)

   Headquarters: Zurich, Switzerland
   Key Offering: Custom chiral synthesis of (R)-2‑Hydroxybutyrolactone for high‑value specialty chemicals

   Biosynth’s expertise in asymmetric catalysis allows it to deliver tailor‑made intermediates for niche pharmaceutical and agrochemical projects, often in collaboration with academic partners.

   Sustainability & Growth Initiatives:

   • Development of catalyst recycling protocols to lower raw‑material consumption
   • Implementation of green solvent alternatives in all synthetic routes
   • Active engagement with the Swiss Chemical Industry Association’s sustainability forum

7. Enamine Ltd. (Ukraine)

   Headquarters: Kyiv, Ukraine
   Key Offering: Rapid‑turnaround synthesis of (R)-2‑Hydroxybutyrolactone for research laboratories and small‑scale manufacturers

   Enamine’s flexible production model supports fast prototyping and small‑batch demand, making it a go‑to supplier for academic and biotech entities.

   Sustainability & Growth Initiatives:

   • Use of renewable electricity for all production facilities
   • Implementation of closed‑loop water recycling systems
   • Partnerships with European universities to develop next‑generation biocatalysts

8. Hairui Fine Chemicals Co., Ltd. (China)

   Headquarters: Guangzhou, China
   Key Offering: Technical‑grade (R)-2‑Hydroxybutyrolactone for bulk chemical manufacturing

   Hairui’s cost‑efficient production processes enable it to supply large volumes of technical‑grade intermediates to the fine‑chemical sector.

   Sustainability & Growth Initiatives:

   • Optimization of raw‑material sourcing to reduce carbon footprint
   • Implementation of energy‑saving distillation technologies
   • Compliance with ISO 9001 and ISO 14001 standards

9. Capot Chemical Co., Ltd. (China)

   Headquarters: Shanghai, China
   Key Offering: GMP‑grade (R)-2‑Hydroxybutyrolactone for pharmaceutical intermediates

   Capot’s advanced chiral separation methods and robust quality control ensure consistent delivery of high‑purity chiral intermediates to global pharma clients.

   Sustainability & Growth Initiatives:

   • Adoption of green chemistry principles in all synthesis steps
   • Investment in waste‑minimization technologies for by‑product handling
   • Participation in China’s “Clean Production” certification program

10. Shandong Xinglu Pharmaceutical Technology Co., Ltd. (China)

    Headquarters: Shandong, China
    Key Offering: Custom synthesis of (R)-2‑Hydroxybutyrolactone for advanced therapeutic development

    Shandong Xinglu’s focus on process innovation and high‑purity output supports the development of novel drugs and agrochemical agents.

    Sustainability & Growth Initiatives:

    • Implementation of renewable energy sources for production lines
    • Development of low‑toxicity reaction pathways
    • Active engagement in China’s “Industrial Green Transformation” program

Download FREE Sample Report: (R)-2‑Hydroxybutyrolactone (CAS 56881‑90‑4) Market – View in Detailed Research Report

Get Full Report: (R)-2‑Hydroxybutyrolactone (CAS 56881‑90‑4) Market – View in Detailed Research Report

Outlook

The market is positioned for continued expansion, driven by the need for enantiomerically pure APIs and the growing emphasis on sustainable manufacturing. Asia‑Pacific, particularly China and India, is expected to capture the largest share of new capacity, while North America and Europe maintain strong demand for high‑purity intermediates in advanced therapeutic development.

Future Trends

• Biocatalytic processes will become mainstream, reducing energy and solvent footprints.
• Continuous flow chemistry will accelerate scale‑up, cutting production costs by up to 30%.
• Digital supply‑chain solutions will improve traceability and compliance for chiral intermediates.
• Integration of AI‑driven reaction optimization will shorten development cycles for new chiral routes.